In vitro studies revealed that compounds VI and VII (Table 3) both exhibited anti-cancer and anti-angiogenic effects against hepatocellular carcinoma (HCC), primarily by inhibiting hypoxia-inducible factor-1 alpha (HIF-1α) and c-mesenchymal–epithelial transition receptor (c-Met) signaling. Here, HIF1A is linked to hepatocellular carcinoma.